On the other hand, as a result of decreasing the levels of HER2 in breast cancer cells, metformin can inhibit breast carcinoma cell growth, and inhibition of p70S6K1, an effector of the mTOR pathway, can mediate this effect [51]. This evidence concerns the gene ERBB2 and breast carcinoma.